MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Atara Biotherapeutics Book Value 2011-2026 | ATRA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -38.5 M | -97.3 M | -99.2 M | 127 M | 280 M | 462 M | 291 M | 339 M | 178 M | 254 M | 315 M | 103 M | -11 M | -3.73 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 462 M | -99.2 M | 150 M |
Quarterly Book Value Atara Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.6 M | -35 M | -55.1 M | -97.3 M | -90.5 M | -111 M | -98.3 M | -99.2 M | -50.8 M | 7.45 M | 65 M | 127 M | 187 M | 257 M | 224 M | 280 M | 310 M | 332 M | 399 M | 462 M | 462 M | 462 M | 462 M | 291 M | 291 M | 291 M | 291 M | 339 M | 339 M | 339 M | 339 M | 178 M | 178 M | 178 M | 178 M | 254 M | 254 M | 254 M | 254 M | 315 M | 315 M | 315 M | 315 M | 103 M | 103 M | 103 M | 103 M | 50.1 M | 50.1 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 462 M | -111 M | 191 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 95.5 | -3.88 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Cerus Corporation
CERS
|
65 M | $ 2.59 | -4.78 % | $ 494 M | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Cardiff Oncology
CRDF
|
45.4 M | $ 1.61 | -2.42 % | $ 108 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Cue Biopharma
CUE
|
26.4 M | $ 34.94 | 17.05 % | $ 3.31 B | USA |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Editas Medicine
EDIT
|
27.3 M | $ 3.04 | 1.33 % | $ 270 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
29.3 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Exelixis
EXEL
|
2.16 B | $ 44.42 | 0.57 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
3.84 M | - | 5.93 % | $ 314 M |  Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 22.35 | 0.72 % | $ 3.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Galapagos NV
GLPG
|
3.24 B | $ 28.39 | -0.13 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.27 | 0.49 % | $ 6.83 B |  Spain |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 3.5 | 5.42 % | $ 5.76 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
-14.5 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-10.7 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
ImmuCell Corporation
ICCC
|
27.1 M | $ 8.87 | 1.66 % | $ 80.1 M | USA |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 1.97 | -7.51 % | $ 152 M | Germany |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |